Radioligand Therapy With 177 Lu-PSMA-I&T in Patients With Metastatic Prostate Cancer
Standard
Radioligand Therapy With 177 Lu-PSMA-I&T in Patients With Metastatic Prostate Cancer : Oncological Outcomes and Toxicity Profile. / Demirkol, Mehmet Onur; Esen, Barış; Seymen, Hülya; Şen, Melis; Uçar, Burcu; Kurtuldu, Sevgilay; Mandel, Nil Molinas; Bavbek, Sevil; Falay, Okan; Tilki, Derya; Esen, Tarık.
In: CLIN NUCL MED, Vol. 48, No. 12, 01.12.2023, p. e564-e569.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Radioligand Therapy With 177 Lu-PSMA-I&T in Patients With Metastatic Prostate Cancer
T2 - Oncological Outcomes and Toxicity Profile
AU - Demirkol, Mehmet Onur
AU - Esen, Barış
AU - Seymen, Hülya
AU - Şen, Melis
AU - Uçar, Burcu
AU - Kurtuldu, Sevgilay
AU - Mandel, Nil Molinas
AU - Bavbek, Sevil
AU - Falay, Okan
AU - Tilki, Derya
AU - Esen, Tarık
N1 - Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2023/12/1
Y1 - 2023/12/1
N2 - INTRODUCTION: This study aimed to investigate the oncological outcomes and toxicity profile of 177 Lu-PSMA-I&T radioligand therapy (RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC), as well as our initial experience in metastatic hormone-sensitive prostate cancer (mHSPC).PATIENTS AND METHODS: A total of 38 consecutive patients with metastatic prostate cancer (33 mCRPC and 5 mHSPC) received 177 Lu-PSMA-I&T RLT, with a median of 2 cycles per patient (range, 1-7). Response to RLT was evaluated based on prostate-specific antigen (PSA) changes and imaging response. Clinical progression-free survival and overall survival were used to report oncological outcomes. Toxicity was assessed using the Common Toxicity Criteria for Adverse Events criteria.RESULTS: In mCRPC, 22 (69%), 18 (56%), and 11 (34%) patients achieved any PSA decline, PSA response of ≥30%, and PSA response of ≥50%, respectively. The clinical progression-free survival and overall survival after the first cycle of RLT were 6.3 and 21.4 months, respectively. In mHSPC, 177 Lu-PSMA-I&T RLT resulted in excellent PSA response (93.0%-99.9%) in all cases. Clinical progression and cancer-related mortality occurred in only 1 case. Toxicity profile was favorable in both mHSPC and mCRPC.CONCLUSIONS: 177 Lu-PSMA-I&T RLT demonstrated favorable PSA response (≥30%) in over half of the patients with mCRPC and excellent PSA response in all patients with mHSPC. Toxicity profile was favorable in both mHSPC and mCRPC settings. Further studies are needed to evaluate the role of 177 Lu-PSMA-I&T RLT in the management of metastatic prostate cancer.
AB - INTRODUCTION: This study aimed to investigate the oncological outcomes and toxicity profile of 177 Lu-PSMA-I&T radioligand therapy (RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC), as well as our initial experience in metastatic hormone-sensitive prostate cancer (mHSPC).PATIENTS AND METHODS: A total of 38 consecutive patients with metastatic prostate cancer (33 mCRPC and 5 mHSPC) received 177 Lu-PSMA-I&T RLT, with a median of 2 cycles per patient (range, 1-7). Response to RLT was evaluated based on prostate-specific antigen (PSA) changes and imaging response. Clinical progression-free survival and overall survival were used to report oncological outcomes. Toxicity was assessed using the Common Toxicity Criteria for Adverse Events criteria.RESULTS: In mCRPC, 22 (69%), 18 (56%), and 11 (34%) patients achieved any PSA decline, PSA response of ≥30%, and PSA response of ≥50%, respectively. The clinical progression-free survival and overall survival after the first cycle of RLT were 6.3 and 21.4 months, respectively. In mHSPC, 177 Lu-PSMA-I&T RLT resulted in excellent PSA response (93.0%-99.9%) in all cases. Clinical progression and cancer-related mortality occurred in only 1 case. Toxicity profile was favorable in both mHSPC and mCRPC.CONCLUSIONS: 177 Lu-PSMA-I&T RLT demonstrated favorable PSA response (≥30%) in over half of the patients with mCRPC and excellent PSA response in all patients with mHSPC. Toxicity profile was favorable in both mHSPC and mCRPC settings. Further studies are needed to evaluate the role of 177 Lu-PSMA-I&T RLT in the management of metastatic prostate cancer.
KW - Male
KW - Humans
KW - Prostate-Specific Antigen
KW - Prostatic Neoplasms, Castration-Resistant/pathology
KW - Treatment Outcome
KW - Dipeptides/therapeutic use
KW - Retrospective Studies
KW - Lutetium/therapeutic use
KW - Heterocyclic Compounds, 1-Ring/therapeutic use
U2 - 10.1097/RLU.0000000000004901
DO - 10.1097/RLU.0000000000004901
M3 - SCORING: Journal article
C2 - 37844332
VL - 48
SP - e564-e569
JO - CLIN NUCL MED
JF - CLIN NUCL MED
SN - 0363-9762
IS - 12
ER -
